Food and Drug Administration (FDA) Funding This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Funding Opportunity RFA-NS-24-029 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical tria...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 21, 2023 Category: Research Source Type: funding

Notice of Participation of the Food and Drug Administration in PAR-22-167, Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
Notice NOT-TR-24-005 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 2, 2023 Category: Research Source Type: funding

Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Optional)
Funding Opportunity PAR-23-258 from the NIH Guide for Grants and Contracts. The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP)...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 16, 2023 Category: Research Source Type: funding

PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
Funding Opportunity PA-23-230 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this NOFO are encouraged to submit SBIR grant ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 12, 2023 Category: Research Source Type: funding

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-200 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources ava...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 27, 2023 Category: Research Source Type: funding

NEI Translational Research Program for Therapeutics (R33 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-205 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their p...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 27, 2023 Category: Research Source Type: funding

Check Out These Public Federal Funding Databases to Learn More About Funding at NIH and Other Federal Agencies
We often recommend NIH RePORT (Research Portfolio Online Reporting Tools) site to applicants & awardees because it publicly provides reports, data, and analyses of NIH research activities, including information on NIH expenditures and the results of NIH-supported research. The RePORT suite includes: NIH RePORTER (RePORT Expenditures and Results) allows users to search for funded projects, investigators, publications, and patents (see this NIH Open Mike blog for more). REPORTER also includes information on research projects funded by the Centers for Disease Control and Prevention, Food and Drug Administration, Agenc...
Source: NIH Extramural Nexus - May 9, 2023 Category: Research Authors: NIH Staff Tags: Tips Before You Submit Funding data Source Type: funding

Tobacco Regulatory Science (R01 Clinical Trial Optional)
Funding Opportunity RFA-OD-23-017 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family S...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 3, 2023 Category: Research Source Type: funding

Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
Funding Opportunity RFA-NS-23-012 from the NIH Guide for Grants and Contracts. The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical tria...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 9, 2023 Category: Research Source Type: funding

Innovation Award: COVID-19 and Health Equity (U01) Clinical Trials Not Allowed
Funding for innovative projects that will strengthen and advance COVID-19 health equity research. Areas of interest include studies that support the evaluation of outcomes FDA-approved products and advance understanding of long COVID by demographic data including, but not limited to, ethnicity, race, age, disability, and geography. Geographic coverage: Nationwide -- Food and Drug Administration, U.S. Department of Health and Human Services (Source: Funding opportunities via the Rural Health Information Hub)
Source: Funding opportunities via the Rural Health Information Hub - November 14, 2022 Category: American Health Source Type: funding

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
Funding Opportunity RFA-OD-22-024 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory auth...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 10, 2022 Category: Research Source Type: funding

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)
Funding Opportunity RFA-OD-22-023 from the NIH Guide for Grants and Contracts. The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01) is to provide support and protected time (three, four, or five years) for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. Research projects must address the research priorities related to the regulatory auth...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 10, 2022 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
Funding Opportunity RFA-HL-23-020 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA) support the Regenerative Medicine Innovation Project (RMIP), which aims to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trials rationale, design, analytic techniques, protocols, and procedures in a Manual of Pr...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 7, 2022 Category: Research Source Type: funding

Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-HL-23-019 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator- initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Appl...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 7, 2022 Category: Research Source Type: funding

Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 Clinical Trial Required)
Funding Opportunity RFA-HL-23-017 from the NIH Guide for Grants and Contracts. The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Appl...
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 7, 2022 Category: Research Source Type: funding